Langer S, Singer C F, Hudelist G, Dampier B, Kaserer K, Vinatzer U, Pehamberger H, Zielinski C, Kubista E, Schreibner M
Department of Obstetrics and Gynecology, Division of Senology, Medical University of Vienna, Austria.
Eur J Gynaecol Oncol. 2006;27(4):345-52.
The activator protein-1 (AP-1) is a dimeric transcription factor formed by members of the Jun and Fos protein family. AP-1 plays a role in a variety of physiological functions including cell proliferation and differentiation, although both c-Jun and c-Fos have also been implicated in oncogenic transformation and tumor progression. To further elucidate the role of AP-1 in breast cancer, we have investigated the expression of the AP-1 proteins c-Jun, JunB, JunD, phosphorylated c-Jun, c-Fos, Fral, Fra2 and the tumor supressor protein p53.
Protein expression was evaluated on a breast cancer tissue microarray with 58 lymph node positive or negative breast cancer specimens, 29 corresponding lymph node metastases, and 11 tissue samples from surrounding tumor-free tissue, each cored as triplicate. Jun and Fos protein family expression was evaluated by immunohistochemistry and was correlated with clinicopathological parameters.
High expression levels were observed for c-Jun, JunD, c-Fos and Fra2, whereas JunB and Fral exhibited lower staining. c-Jun protein expression was correlated to Fral staining (p = 0.007, Kendall's Tau) and Fral was further associated with c-Fos (p < 0.001), JunD (p = 0.001) and Fra2 (p = 0.011) expression. JunD expression correlated with c-Fos (p < 0.001), JunB (p = 0.035) and c-Jun (p = 0.05). Activated c-Jun correlated with c-Fos expression (p = 0.041). JunB was negatively correlated to tumor stage, (p = 0.093, corr coeff. = -0.293, Spearman's correlation) but was significantly increased in nodal negative tumors (p = 0.004, Mann Whitney test). In addition, increased Fral expression showed a trend towards an increased overall survival (p = 0.077, RR = 0.534, Cox regression).
Our results suggest an important role for JunB and Fral in the biological behavior of malignant breast tumors.
活化蛋白-1(AP-1)是一种由Jun和Fos蛋白家族成员组成的二聚体转录因子。AP-1在多种生理功能中发挥作用,包括细胞增殖和分化,尽管c-Jun和c-Fos也与致癌转化和肿瘤进展有关。为了进一步阐明AP-1在乳腺癌中的作用,我们研究了AP-1蛋白c-Jun、JunB、JunD、磷酸化c-Jun、c-Fos、Fral、Fra2以及肿瘤抑制蛋白p53的表达。
在一个包含58个淋巴结阳性或阴性乳腺癌标本、29个相应淋巴结转移灶以及11个来自周围无瘤组织的组织样本的乳腺癌组织微阵列上评估蛋白表达,每个样本取三个芯样。通过免疫组织化学评估Jun和Fos蛋白家族的表达,并将其与临床病理参数相关联。
观察到c-Jun、JunD、c-Fos和Fra2表达水平较高,而JunB和Fral染色较低。c-Jun蛋白表达与Fral染色相关(p = 0.007,肯德尔氏Tau系数),Fral进一步与c-Fos(p < 0.001)、JunD(p = 0.001)和Fra2(p = 0.011)表达相关。JunD表达与c-Fos(p < 0.001)、JunB(p = 0.035)和c-Jun(p = 0.05)相关。活化的c-Jun与c-Fos表达相关(p = 0.041)。JunB与肿瘤分期呈负相关(p = 0.093,相关系数 = -0.293,斯皮尔曼相关性),但在淋巴结阴性肿瘤中显著增加(p = 0.004,曼-惠特尼检验)。此外,Fral表达增加显示出总生存期增加的趋势(p = 0.077,风险比 = 0.534,Cox回归)。
我们的结果表明JunB和Fral在恶性乳腺肿瘤的生物学行为中起重要作用。